Search Results
Research-Track Residents | Psychiatry
... rigorous training. These pages hope to introduce you to who they are with the hope that their enthusiasm ... the consciousness-altering properties of psilocybin can be harnessed to treat patients with mental illness. Joseph ...
Hallucinogenic Drug Helps Patients with Advanced Cancer
NYU Langone study finds the hallucinogenic drug psilocybin, when combined with counseling, relieves depression and anxiety in cancer patients.
Psychedelic Drug Benefits Persist in People with Cancer
NYU Langone study finds a psychedelic drug improved emotional distress in people with cancer for nearly five years after treatment.
Novel Therapeutic Agents for Hard-to-Treat Mental Conditions
NYU Langone’s Dr. Michael P. Bogenschutz, Dr. Stephen Ross, and colleagues explore therapeutic agents such as psilocybin, cannabidiol, and MDMA.
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
The purpose of this research is to compare the effectiveness of psilocybin to Diphenhydramine (Benadryl) in the treatment of alcohol dependence. Psilocybin is the active ingredient in many types of hallucinogenic mushrooms. A hallucinogen is a type of drug that can make you see, hear, feel, taste, and/or smell something that is not real. Psilocybin has not been approved by the United States Food and Drug Administration (FDA) as a safe or effective treatment for any health condition. Therefore, the use of psilocybin to treat any disorder is considered experimental. Pilot studies have investigated its effects in alcohol dependence and smoking cessation (quitting smoking). There have not been any published controlled studies of the use of psilocybin in the treatment of alcohol dependence. Diphenhydramine is an antihistamine (anti-allergy medication), which is used to treat allergic reactions, insomnia (trouble sleeping), motion sickness, and Parkinsonism (a condition of the brain that affects movement). We are comparing the effectiveness of diphenhydramine to psilocybin in the treatment of alcohol dependence because it can have physical and psychological effects similar to psilocybin at the doses used in this study.
A Multi-Center Randomized Double-Blind Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
The purpose of this research is to study the medical and safety effects of a single dose of an investigational drug called psilocybin compared to an active placebo in participants with Major Depressive Disorder (MDD) who are otherwise medically healthy. When someone experiences persistent and intense feelings of sadness for extended periods of time, then they may have MDD. If you decide to participate in this study, you will undergo a psychological exam to determine if you have MDD. For purposes of this consent form, the term “depression” refers to MDD. “Investigational” means that the study drug has not been approved by the U.S. Food and Drug Administration (FDA) for clinical use. However, we have permission from the FDA and the Drug Enforcement Agency (DEA) to use this drug in this research study. This is a randomized, double-blind, placebo-controlled research study. “Randomized” means you have an equal chance of getting either the psilocybin or active placebo and you do not get to choose which one you get. “Double-blind” means neither you nor the study team will know if you are taking psilocybin or the active placebo.
